INOmax® - Pharmaceutical grade Nitric Oxide1
INOmax®, in conjunction with ventilatory support and other appropriate agents, is indicated2:
- for the treatment of near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation.
- to selectively decrease pulmonary arterial pressure in patients with perioperative pulmonary hypertension in conjunction with heart surgery.
The Therapeutic Goods Administration (TGA) specifies that INOmax must be delivered through an approved nitric oxide delivery system meeting specific quality and safety criteria.
INOmax® Delivery Systems
INOmax DSIR® Plus is designed to provide uninterrupted delivery of iNO to help ensure patient safety and reduce the possibility of rebound pulmonary hypertension.
- State-of-the-art innovations including on-screen pre-use checkout, calibrations and cell failure notifications
- Quick access to patient and diagnosis information, including a detailed alarm history, to help ensure comprehensive monitoring
- Validated with 80+ ventilation systems3
INOmax Total Care®
When moments count, count on the trusted total service package that delivers uninterrupted support for INOmax® gas for inhalation.2
- Global support with INOmax® since 2000
- More than 70,000 patients treated worldwide4
- Comprehensive support package ensuring reliable response for delivery of drug, device and consumables across Australia
- Online training available for our healthcare customers
- 24/7 technical support
CYLINDER ORDERS/COLLECTIONS
Order INOmax® gas cylinders or request collection of empty cylinders
ORDER CONSUMABLES
Order consumables for use with INOmax® devliery systems
UPLOAD USAGE
Submit your INOmax® usage online
References
- Miller, Ol et al. Lancet 2000;356(9240):1464-9
- INOmax® Australian Product Information
- INOmax DSIR® Plus Operator Manual. Rev 01,2015
- Date on file, Mallinckrodt